Genomic Health (GHDX) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GHDX Hot Sheet
Price: $63.44 --0%
Financial Fact:
Income (loss) from operations: -16.92M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Income (loss) from operations: -16.92M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Genomic Health (NASDAQ: GHDX) reported Q1 EPS of $0.34, $0.06 better than the analyst estimate of $0.28. Revenue for the quarter came in at $108.8 million versus the consensus estimate of $106.68 million.
- "We expect to achieve double-digit revenue growth for the year with continued growth across key products and look forward to the national reimbursement decision in Germany for the Oncotype DX breast cancer test."
For earnings history and earnings-related data on Genomic Health (GHDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
